Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study

KB Sims(Massachusetts General Hospital), Daniel I. Rosenthal(Massachusetts General Hospital), Seymour Packman(University of California, San Francisco), NJ Weinreb(University Research Co (United States)), Ramnik J. Xavier(Broad Institute), MA Fitzpatrick(SynZyme Technologies (United States)), Paige Kaplan(Children's Hospital of Philadelphia), BE Rosenbloom(Tower Cancer Research Foundation), Jennifer Angell, Henry J. Mankin(Harvard University), J. A. Barranger(University of Pittsburgh), GM Pastores(New York University)
Clinical Genetics
April 7, 2008
Cited by 134


Related Papers